Aquestive CEO Keith Kendall departs; COO Daniel Barber named President & CEO

Aquestive Therapeutics, Inc.

Keith Kendall leaves as President, CEO, and Board member effective May 17, 2022.
Daniel Barber, former COO (since May 2019), appointed President, CEO, and Class I Director.
Kendall receives severance: $262,500 accelerated first three installments plus monthly payments, and $10,000/month consulting fee through Dec 2022.
Kendall will serve as consultant to assist in management transition through end of 2022.
Company states Kendall's departure is unrelated to strategy, operations, or financial condition.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Daniel Barber

President and Chief Executive Officer

AQST · Aquestive Therapeutics, Inc.

Effective: 2022-05-17
Filed: May 17, 2022, 7:59 PM ET

Effective May 17, 2022, the Board appointed Daniel Barber, Senior Vice President and Chief Operating Officer of the Company, to the position of President and Chief Executive Officer of the Company.

Departed

Keith J. Kendall

President and Chief Executive Officer

AQST · Aquestive Therapeutics, Inc.

Effective: 2022-05-17
Successor: Daniel Barber
Filed: May 17, 2022, 7:59 PM ET

On May 17, 2022, Aquestive Therapeutics, Inc. (the “Company”) announced that Keith J. Kendall, President and Chief Executive Officer of the Company, is leaving the Company and Board of Directors (the “Board”) effective May 17, 2022.

Appointed

Daniel Barber

Class I Director

AQST · Aquestive Therapeutics, Inc.

Effective: 2022-05-17
Filed: May 17, 2022, 7:59 PM ET

In addition, the Board appointed Mr. Barber to fill the vacancy on the Board due to Mr. Kendall’s departure, to serve as a Class I Director with a term expiring at the Company’s 2022 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Barber was appointed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Effective May 17, 2022, the Board appointed Daniel Barber, Senior Vice President and Chief Operating Officer of the Company, to the position of President and Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith J. Kendall departed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..

Action: leaving
Role: President and Chief Executive Officer

Exact text from the filing

On May 17, 2022, Aquestive Therapeutics, Inc. (the “Company”) announced that Keith J. Kendall, President and Chief Executive Officer of the Company, is leaving the Company and Board of Directors (the “Board”) effective May 17, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Daniel Barber was appointed as Class I Director at Aquestive Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

In addition, the Board appointed Mr. Barber to fill the vacancy on the Board due to Mr. Kendall’s departure, to serve as a Class I Director with a term expiring at the Company’s 2022 Annual Meeting of Stockholders.

View on SEC.gov

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-019590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.